Spending like a bigger company on purpose: current results carry the cost of an expansion aimed at demand management say
The model's full reasoning — Q4 2023 call → NOWe need to determine if management acknowledges that current results are weighed down by an expansion already undertaken, and justifies it with demand already real. Let's examine the transcript. Key points: Management discusses various projects: Clean Sugar (dextrose) at Shenandoah, 60% protein commercialization, Tharaldson JV, carbon capture in Nebraska, Shell Fiber Conversion Technology at York. They mention costs, capital expenditures, and that they are in the process of commissioning. They also mention that they have strong demand, negotiations, etc. Specifically, on the expansion cost: They mention capital spend for 2023 was $109 million, and 2024 CapEx expected $125-150 million. They talk about the start-up of Clean Sugar, the Tharaldson JV, etc. But do they explicitly say that these expansions are weighing on current results? They mention that they are in the process of commissioning, and that they have not yet fully ramped up. For example, on protein, they say "we have started to sell 60% protein" but it's early. On dextrose, they say "we will be ready to begin delivering product in the beginning of the second quarter." So it's not yet delivering. They also mention that they have built inventory of 60% protein. But do they say that the cost of these expansions is depressing current profitability? They talk about SG&A increase due to consulting and professional fees, and stock-based compensation. They also mention that they have a lot of projects. But they don't explicitly say "our current results are being weighed down by the cost of expansion." They do say that they are investing in growth, but they don't frame it as a burden on current results. They also mention that they have strong demand and negotiations, but is that "already real" demand? They say "we have enough identified demand that could take all of our product" for 60 pro, but that's not yet committed. They are in negotiations. For dextrose, they are in late-stage negotiations. So the demand is not yet fully realized in terms of contracts. They also mention that they are building capacity ahead of revenue. But the question is whether management acknowledges that this is weighing on current results. They do mention that they have higher SG&A due to consulting and professional fees, but that's not directly tied to expansion.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
SIBN · Q3 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken — spending, hirin...YES Management explicitly describes the expansion as already underway and costing the company now: investments in sales force (85 territory managers + 72 specialists), new products (iFuse-TORQ, iFuse-Bedrock Granite), instrument trays, inventory, and R&D that are driving higher depreciation, freight, and product costs 84% gross margin (down low-single digits from these factors). Anshul confirms “we’ve made a substantial amount of investment whether it’s in TORQ trays or Granite trays or TORQ implants” and “this is going to lead to elevated depreciation,” while Laura notes the build supports “strong new product demand.
FLYW · Q1 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES The transcript shows management explicitly linking the current EBITDA decline to the hiring expansion already completed ("increased the number of FlyMates by over 50% during the past year" and "added over 100 new FlyMates within the sales, marketing and product functions"), while framing the spending as a deliberate, ongoing 2022 investment plan that is already delivering observable results through record client adds (130), pipeline growth, and strong ARR signings.
EVGO · Q2 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES Management describes concrete expansion already underway—170 stalls placed in Q2, total stalls at 2,397 with 460 under construction, pipeline at 3,669, CapEx jumped to $44 million to accelerate deployment, and G&A ramping personnel to support growth—while directly tying the resulting negative adjusted EBITDA of -$19.8 million to that deliberate build-out.